Use of thiazolidinediones does not affect prostate-specific antigen levels in men with diabetes

Tunghi M. Pini, Marie R. Griffin, Christianne L. Roumie, Mary Margaret Huizinga, Jay H. Fowke, Robert Greevy, Xulei Liu, Harvey J. Murff

Research output: Contribution to journalArticle

Abstract

Thiazolidinediones (TZD) have been shown to down-regulate prostate-specific antigen (PSA) levels in prostate cancer cell lines and decrease PSA velocity among prostate cancer patients; however, the effect of TZDs on serum PSA levels among men with diabetes at risk for prostate cancer is unknown. We conducted a retrospective cohort study of veterans receiving care for diabetes between 1999 and 2005 to determine if TZD use affects PSA levels in veterans at risk for prostate cancer. Eligible patients were male, ≥45 years old, taking at least one oral antidiabetic medication, and with two or more recorded PSA values. Patients with a prior history of prostate cancer or prostatectomy were excluded. Of the 13,791 patients included in the adjusted analysis, 2,016 (14.6%) were prescribed a TZD. No effect of cumulative TZD dose on change in PSA was detected (P = 0.26). Increased TZD exposure was not associated with a change in PSA, suggesting that TZD treatment for diabetes is unlikely to affect prostate cancer detection.

Original languageEnglish (US)
Pages (from-to)1937-1938
Number of pages2
JournalCancer Epidemiology Biomarkers and Prevention
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2009

    Fingerprint

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this